About Prywatny Gabinet Lekarski
Clinical Trials at Prywatny Gabinet Lekarski
During the past decade, Prywatny Gabinet Lekarski conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on
average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Clinical Trials Sponsors and Collaborators
Clinical Trials Conditions at Prywatny Gabinet Lekarski
According to Clinical.Site data, the most researched conditions in "Prywatny Gabinet Lekarski" are
"Myasthenia Gravis" (1 trials) and "Polyradiculoneuropathy, Chronic Inflammatory Demyelinating" (1 trials). Many other conditions were trialed in "Prywatny Gabinet Lekarski" in a lesser frequency.
Clinical Trials Intervention Types at Prywatny Gabinet Lekarski
Most popular intervention types in "Prywatny Gabinet Lekarski" are "Drug" (2 trials). Other intervention types were less common.
The name of intervention was led by "Nipocalimab" (2 trials) and "Placebo" (2 trials). Other intervention names were less common.
Clinical Trials Genders at Prywatny Gabinet Lekarski
The vast majority of trials in "Prywatny Gabinet Lekarski" are
2 trials for "All" genders.
Clinical Trials Status at Prywatny Gabinet Lekarski
Currently, there are NaN active trials in "Prywatny Gabinet Lekarski".
undefined are not yet recruiting,
2 are recruiting,
undefined are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were undefined completed trials in Prywatny Gabinet Lekarski,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Prywatny Gabinet Lekarski, 0 "Phase 1"
clinical trials were conducted, 1 "Phase 2" clinical
trials and 2 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".